Healing & Repair
Limited / unverified FDA safety flag Limited / unverified Anti-inflammatory Immunity
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 10 mg
Dosing window: Anytime
Receptor / target: Alpha-MSH
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 200mcg - 500mcg daily | Standard protocol for systemic inflammation or gut repair. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 200 mcg 1x Daily | |
| Week 2 | 300 mcg 1x Daily | |
| Week 3 | 400 mcg 1x Daily | |
| Weeks 4-8 | 500 mcg 1x Daily |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2: Injury Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 500 mcg 2-3x Daily | Administer at or near the injury or inflammation site. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Repair protocols depend on injury type, timing, loading, inflammation, and angiogenesis risk. Rodent or cell data can suggest a mechanism, but it does not prove a human dose or replace rehab and diagnosis. Entry context: target (Alpha-MSH); route Subcutaneous; timing Anytime. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added.
Independent evidence
Independent safety notes: FDA states it has not identified human exposure data for KPV administered by any route.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Known hypersensitivity to KPV, alpha-MSH-derived peptides, or any formulation excipients. Limited / unverified
- Concurrent use of immunosuppressive biologic agents (TNF-alpha inhibitors, IL-6 inhibitors, JAK inhibitors): additive anti-inflammatory pathway inhibition may push the immune response below the threshold needed for pathogen defense; theoretical but warrants clinical consideration. Limited / unverified
- Concurrent corticosteroid use: overlapping NF-kB suppression; the additive anti-inflammatory effect may mask warning signs of infection or worsen immune suppression. Limited / unverified
- Active infections requiring a robust acute immune response: KPV's NF-kB inhibition, while selective, may blunt cytokine response to active bacterial or viral infections at high doses. Limited / unverified
- Pregnancy: no clinical safety data; melanocortin receptor signaling has developmental implications. Limited / unverified
- Breastfeeding: no established safety data. Limited / unverified
- Pediatric use: safety not established. Limited / unverified
- PepT1-negative intestinal conditions: rare congenital PepT1 deficiency would abolish oral/enteric KPV activity. Limited / unverified
Side effects (limited evidence)
- Mild injection site redness and irritation: the most commonly reported adverse effect; localized erythema at the subcutaneous administration site; transient; self-resolving. Limited / unverified
- Mild gastrointestinal discomfort: particularly with oral or higher-dose administration; nausea, loose stools, or abdominal cramping; more common in the first week. Limited / unverified
- Temporary fatigue: reported in a minority of subjects; likely related to systemic inflammatory modulation during early treatment. Limited / unverified
- Headache: uncommon; transient. Limited / unverified
- Skin flushing: rare; mild; may reflect residual melanocortin receptor activity. Limited / unverified
- Mild dizziness: infrequent; mechanism unclear. Limited / unverified
- Temporary appetite changes: rare; MC4R activity (which KPV may weakly engage) has minor effects on appetite regulation. Limited / unverified
- Potential blunting of acute immune response at very high doses: KPV's NF-kB inhibition is dose-dependent; at supraphysiologic doses, the anti-inflammatory effect could theoretically impair the acute phase immune response to active infection. Limited / unverified
- Allergic reactions to compounding excipients: redness, hives, stinging at injection site; relates to the compounding vehicle rather than KPV itself. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
KLOW (BPC-157 + TB-500 + KPV + GHK-Cu)tri-heal-blend